Ovid Therapeutics (OVID) Current Leases (2022 - 2026)

Ovid Therapeutics (OVID) has reported Current Leases for 5 consecutive years, with $1.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Leases rose 7.23% year-over-year to $1.5 million; the trailing twelve-month figure through Jun 2026 stood at $1.5 million (up 7.23% YoY), and the FY2025 full-year result was $1.4 million, up 7.26% from the prior year.
• Current Leases grew to $1.5 million in Q2 2026 per OVID's latest filing, from $1.5 million in the prior quarter.
• Across five years, Current Leases topped out at $1.5 million in Q2 2026 and bottomed at $533946.0 in Q4 2022.
• Historically, Current Leases has averaged $1.2 million across 5 years, with a median of $1.3 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Current Leases surged 133.36% in 2023, then climbed 7.2% in 2025.
• Over 5 years, Current Leases stood at $533946.0 in 2022, then soared by 133.36% to $1.2 million in 2023, then increased by 7.22% to $1.3 million in 2024, then gained by 7.26% to $1.4 million in 2025, then increased by 3.56% to $1.5 million in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $1.5 million, $1.5 million, and $1.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.